Abstract library

14 results for "McNamara".
#219 Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide
Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Philippe Ruszniewski
#1345 To Evaluate How the Outcome of Neuroendocrine Tumour (NET) Multidisciplinary Team (MDT) Meeting Decisions Are Conveyed to Patients at a ENETS Centre of Excellence (The Christie) and How This Service Can Be Further Improved
Introduction: It is recommended that people with cancer should be managed by an MDT and the outcomes should be communicated in a “timely manner”. However, it does not specify when this should be done, or by whom.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Christina Rigby
Authors: Rigby C, Mansoor W, Valle J, Hubner R, ...
#1356 Safety and Compliance of Capecitabine and Temozolomide in Patients with Advanced Neuroendocrine Tumours
Introduction: Capecitabine-temozolomide (CAPTEM) is a treatment option in patients (pts) with neuroendocrine tumours. Although efficacy data has been reported, no detailed safety information exists.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Georgios Papaxoinis
#1492 Prospective Validation of Prognostic Score in High-Grade Gastrointestinal Neuroendocrine Carcinomas (GI-NECs)
Introduction: Prognostic markers for risk-stratification of GI-NECs are lacking.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Angela Lamarca
#1680 PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs).
Introduction: Treatment options for patients with advanced Wd SB-NETs are limited.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Angela Lamarca
Keywords: immunotherapy
#1849 Mixed Adeno-Neuroendocrine Carcinoma (MANEC) of the Gastrointestinal (GI) Tract: Experience of a European Neuroendocrine Tumour Society (ENETS) Centre of Excellence
Introduction: Knowledge of MANECs is limited
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Melissa Frizziero
#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).
Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso
#2034 International Survey of Clinical Practice Exploring Use of Platinum-Etoposide Chemotherapy for Extra-Pulmonary High Grade Neuroendocrine Carcinoma (EP-G3-NEC)
Introduction: Platinum-etoposide (PE) chemotherapy (CH) is a globally established combination for EP-G3-NEC; the optimal schedule has not been established.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Angela Lamarca
#2107 Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumour Society Centre of Excellence
Introduction: Carboplatin-Etoposide is a first-line option for patients (pts) with advanced EP-PD-NEC. Data from randomised trials are lacking
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Melissa Frizziero
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team